Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Doran

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Bioorganic & Medicinal Chemistry Letters|September 29, 2015
Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylaseDaniel W Kung, David A Griffith, William P Esler, et al.
Journal of Medicinal Chemistry|August 29, 2013
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structureDavid A Griffith, Robert L Dow, Kim Huard, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Journal of Medicinal Chemistry|February 20, 2015
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug designChristopher R Butler, Michael A Brodney, Elizabeth M Beck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
First-in-Human Evaluation of <sup>18</sup>F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4BYuichi Wakabayashi, Per Stenkrona, Ryosuke Arakawa, et al.
Journal of Medicinal Chemistry|March 18, 2015
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitorsMichael A Brodney, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|May 31, 2018
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)Jon H Come, Philip N Collier, James A Henderson, et al.
Journal of Medicinal Chemistry|April 4, 2018
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking HypopigmentationBrian T O'Neill, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|August 19, 2020
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver TargetingKim Huard, Aaron C Smith, Gregg Cappon, et al.
Iucrj|October 9, 2014
Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1Ho-Hsien Lee, Irene Cherni, HongQi Yu, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Bioorganic & Medicinal Chemistry Letters|September 29, 2015
Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylaseDaniel W Kung, David A Griffith, William P Esler, et al.
Journal of Medicinal Chemistry|August 29, 2013
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structureDavid A Griffith, Robert L Dow, Kim Huard, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Journal of Medicinal Chemistry|February 20, 2015
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug designChristopher R Butler, Michael A Brodney, Elizabeth M Beck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
First-in-Human Evaluation of <sup>18</sup>F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4BYuichi Wakabayashi, Per Stenkrona, Ryosuke Arakawa, et al.
Journal of Medicinal Chemistry|March 18, 2015
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitorsMichael A Brodney, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|May 31, 2018
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)Jon H Come, Philip N Collier, James A Henderson, et al.
Journal of Medicinal Chemistry|April 4, 2018
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking HypopigmentationBrian T O'Neill, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|August 19, 2020
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver TargetingKim Huard, Aaron C Smith, Gregg Cappon, et al.
Iucrj|October 9, 2014
Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1Ho-Hsien Lee, Irene Cherni, HongQi Yu, et al.
Pageof 7